Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
MDA5 pathway
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "MDA5 pathway" in MCE Product Catalog:
6
6 Cited Publications
Target:
Research Areas:
AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
6
6 Cited Publications
Target:
Research Areas:
AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects .
Cat. No.: HY-160229
Synonyms: R-1075 sodium
Target:
Toll-like Receptor (TLR) MyD88 Caspase Reactive Oxygen Species (ROS) Autophagy Pyroptosis HIV
Research Areas:
ssRNA40 sodium (R-1075 sodium) is a single-stranded RNA40 derived from HIV-1. ssRNA40 sodium activates the TLR7, TLR8, TLR2, RIG-I, MDA5, MyD88, Caspase-3, IRE1α, NLRP3 inflammasome and IRF7 signaling pathways. ssRNA40 sodium alters mRNA expression in neutrophils, induces pro-inflammatory cytokines, ROS, autophagy (autophagy), pyroptosis (pyroptosis), neuronal death, neurodegeneration, aggregate formation and NK cell activation. ssRNA40 sodium activates the expression of CD62L, CD11b, CD69, MX1, OAS1, ATG7, LC3B and XBP1 in immune cell and neuronal populations. ssRNA40 sodium causes cortical neuron loss and axonal damage in mice in a TLR7-dependent manner. ssRNA40 sodium can be used in research on HIV-1 infection, neurodegeneration, COVID-19 and HIV-associated neurological disorders .
Cat. No.: HY-W682115
CAS No.: 30811-80-4
Synonyms: Polycytidylic acid
Research Areas:
Poly(C) (Polycytidylic acid) is a pleiotropic immunostimulant that specifically binds to TLR3, RIG-I and MDA5 receptors. Poly (C) recruits adaptor proteins to activate downstream signaling pathways and induce the production of type I interferons and inflammatory cytokines. Poly (C) triggers cancer cell apoptosis via the intrinsic or extrinsic caspase pathway, thereby exerting inhibitory effects on tumor growth and metastasis. Poly (C) acts as a vaccine adjuvant to modify the tumor microenvironment, regulate the expression of endothelial adhesion molecules and induce virus-like immune responses. Poly (C) can be applied to research related to melanoma, various solid tumors, hematological malignancies and autoimmune insulin-dependent diabetes mellitus .
Cat. No.: HY-181440
CAS No.: 3092641-80-7
Target:
Research Areas:
TDG-IN-1 is an orally active, selective small-molecule inhibitor of thymine DNA glycosylase (TDG) with a Ka of 1.46 nM. TDG-IN-1 impairs the DNA-binding ability of TDG, induces downregulated expression of DHX9, accumulation of double-stranded RNA, and activation of the RIG-I/MDA5-MAVS pathway, while acting as a tumor suppressor, innate immune activator and immunostimulant. TDG-IN-1 inhibits the growth of p53-deficient tumor cells and xenograft tumors, and exerts a synthetic lethal effect with p53. TDG-IN-1 is applicable to the research of p53-deficient cancers .
Cat. No.: HY-187997
Target:
Research Areas:
ADAR1-IN-2 is an adenosine analog and an orally active ADAR1 inhibitor with antiproliferative activity against multiple ADAR1-dependent cancer cell lines. ADAR1-IN-2 inhibits ADAR1-mediated A‑to‑I editing of partial RNA substrates (APOBEC3D), thereby activating the RIG‑I/MDA5‑MAVS signaling pathway, inducing G0/G1 cell cycle arrest and apoptosis in tumor cells, and suppressing tumor cell migration and invasion. ADAR1-IN-2 inhibits tumor growth in DU-145 and HUCCT1 xenograft models. ADAR1-IN-2 can be used in research related to cancers such as prostate cancer and breast cancer .
Cat. No.: HY-126675G
CAS No.: 2241300-51-4
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
